GLRX

Across TCGA pan-cancer cohorts, GLRX mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GLRX data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GLRX mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GLRX expression acts as an unfavorable survival marker.

CCRCC, GBM, and HNSC are the cancer types where GLRX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.489	0.950	.001	19	view →
GBM	DFS	Quartile	All	0.528	0.791	.005	15	view →
HNSC	DFS	Quartile	II,III,IV	0.868	0.986	.029	10	view →
PDAC	DFS	Tertile	IV	0.217	0.550	.024	5	view →
LUAD	OS	Tertile	III,IV	0.212	0.652	.022	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GLRX–CCRCC (DFS)

Open the CCRCC breakdown →